According to data, 1.5% of the U.S. population has hereditary breast and ovarian cancer syndrome (0.72%), Lynch syndrome (0.35%), or familial hypercholesterolemia (FH; 0.43%). This
Lynch syndrome
Lynch syndrome
Simultaneous Population-Based Testing for Specific Cancer Genes, Including Lynch Syndrome, Found Conditionally Cost-Effective
No Metachronous Cancers Observed in MSH6 and PMS2 Carriers
Lynch syndrome is caused by germline mutations in MLH1, MSH2, MSH6, or PMS2 genes, but the most commonly affected genes are MLH1 and MSH2. Increasingly, surveillance recommendations are on a gene-specific basis, with
Using Family History to Guide Surveillance of “Other” Cancers in Lynch Syndrome: Does That Work?
The “other” cancers in Lynch syndrome include small-bowel, pancreatobiliary, urinary tract, and brain cancers, as well as sebaceous neoplasms. Routine screening for many of these
Individual Patient Data Meta-Analysis of Randomized Trials Fails To Show Benefit of Chromoendoscopy in Lynch Syndrome
An individual patient data meta-analysis, which was performed for this study, utilizes the individual data from separate studies rather than summary data. However, this study
Lynch Syndrome Colonoscopy: Quality Matters
In the U.S., colonoscopy is usually performed at 1- to 2-year intervals in Lynch syndrome. This multicenter study evaluated the relationship of adenoma detection and
Not Asking Enough Questions: Low Rates of Recommending and Receiving Genetic Testing in U.S. in Those at Risk for Lynch Syndrome
Douglas K. Rex, MD, FASGE reviewing Faust N, et al. Gastroenterology 2019 Dec 6. The National Health Interview Survey is conducted every 5 years and
